Abstract

The rat IgM monoclonal antibody B23.1 was found to bind to mononuclear phagocytes that had matured beyond the monoblast stage. Macrophages from several anatomical sites, elicited by different means, as well as those cultured from bone marrow precursors, bound B23.1 antibody. The increase, with time, of B23.1-positive cells in the nonadherent fraction of cultured bone marrow paralleled that of immature mononuclear phagocytes as detected by esterase staining. Treatment of freshly explanted bone marrow cells with B23.1 and complement did not reduce the number of macrophage colony-forming cells (monoblasts) in that population. Treatment with B23.1 antibody alone did not alter the activation of macrophages for tumor cell killing; however, with added complement, B23.1 reduced activated macrophage-mediated cytotoxicity to background levels. In similar studies B23.1 and complement did not affect antibody production by B cells, the cytotoxic capacity of T cells, or NK cell-mediated lysis. These data indicate that antibody B23.1 is useful for either the detection or elimination of mouse mononuclear phagocytes from the promonocyte stage to that of the mature macrophage.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call